Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of “Buy” from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $66.75.

A number of research firms recently commented on ARCT. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a report on Monday, January 13th.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new position in Arcturus Therapeutics in the second quarter valued at about $596,000. Point72 DIFC Ltd acquired a new position in Arcturus Therapeutics during the 2nd quarter valued at about $188,000. Squarepoint Ops LLC bought a new position in shares of Arcturus Therapeutics in the 2nd quarter valued at about $718,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Arcturus Therapeutics during the 2nd quarter worth approximately $142,000. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of Arcturus Therapeutics during the second quarter worth approximately $958,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $16.79 on Friday. Arcturus Therapeutics has a 52-week low of $14.30 and a 52-week high of $45.00. The stock has a fifty day moving average price of $17.46 and a two-hundred day moving average price of $19.85. The firm has a market capitalization of $454.84 million, a P/E ratio of -7.56 and a beta of 2.63.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same period last year, the firm posted ($0.61) EPS. On average, equities research analysts predict that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.